Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed Mullerian tumors. The British Columbia Cancer Agency experience. Gynecol Oncol Jan 2008;108(1):58-62.Hoskins PI, Le N, Ellard S, et al. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mu...
Carboplatin plus paclitaxel is associated with improved QOL, compared with cisplatin plus etoposide, in non-small-cell lung cancerCarboplatin, therapeutic useCisplatin, therapeutic useEtoposide, therapeutic useNon-small-cell-lung-cancer, treatment
Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): Activity and s... Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer: activity...
The safety of carboplatin plus paclitaxel in combination with bevacizumab (CP-B) in patients with ILD and lung cancer (ILD-LC) remains to be clarified. In the present study, the safety and efficacy of CP-B treatment in ILD-LC patients were retrospectively investigated. Four patients, who ...
RichardetandFCóppolaandSJovtisandLSDOSLung CancerJohnson D, Paul D, Hande K. Paclitaxel plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 1996;14:2054.Johnson DH,Paul DM,Hande KR,et al.Paclitaxel plus carboplatin in advanced non-small cell lung cancer. Journal of ...
Based on their good activity and minimal toxicity in non-small cell lung cancer and other cancers, we initiated a phase II trial of carboplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in the treatment of patients with previously untreated stage IIIB and IV non-...
Paclitaxel-carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med. 2006;355(24):2542-255017167137PubMedGoogle ScholarCrossref 7. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as ...
We aimed to evaluate the efficacy and safety of carboplatin plus weekly paclitaxel with bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC). Patients with stage IIIB/IV or postoperative recurrent NSCLC (n=33) were treated with carboplatin (area under the curve of...
INTRODUCTION: This phase II trial evaluated the efficacy and toxicity of the combination of paclitaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with carcinoma of unknown primary site (CUP). METHODS: Patients with previously untreated CUP (adenocarcinoma, poorly ...
Weekly paclitaxel plus carboplatin has comparable efficacy to standard paclitaxel/carboplatin therapy, and favourable tolerability, in NSCLC